2′-O-methyluridine CAS:2140-76-3

2'-O-Methyluridine (meU) is a modified nucleoside derived from uridine, characterized by the addition of a methyl group at the 2' hydroxyl position of the ribose sugar. This subtle modification significantly impacts the chemical properties and biological functions of RNA molecules. The presence of a methyl group enhances the stability of RNA by protecting it from degradation by ribonucleases, enzymes that typically degrade RNA strands. As a result, 2'-O-methylated nucleotides are often found in the structures of functional RNAs, such as tRNAs and rRNAs, where they contribute to the overall stability and structural integrity. In mRNA, the incorporation of 2'-O-methyluridine can enhance translation efficiency and influence the interaction of the mRNA with ribosomes and other cellular machinery involved in protein synthesis. This is particularly important for the regulation of gene expression, where modifications to the mRNA molecule can dictate the rate and timing of protein production. The therapeutic potential of 2'-O-methyluridine has garnered significant attention in the field of molecular medicine. Modified RNA molecules incorporating 2'-O-methyluridine are being explored for use in vaccines, particularly mRNA vaccines, as seen in some COVID-19 vaccinations. These modifications can improve vaccine efficacy by enhancing immune responses and ensuring the stability of the mRNA in vivo. Moreover, research into 2'-O-methyluridine continues to expand, with implications for RNA-based therapeutics, including antisense oligonucleotides and small interfering RNAs (siRNAs). By leveraging the unique properties of this modified nucleoside, scientists aim to develop more effective strategies for treating various diseases, including viral infections and genetic disorders. In summary, 2'-O-methyluridine is a critical player in RNA biology, offering insights and opportunities for advancements in both basic research and therapeutic development.